Fig. 6: FSP1 is upregulated in KRAS-mutated cancers and correlates with poor relapse-free survival.

a Log²-transformed RPKM expression data for FSP1 (AIFM2) for the indicated TCGA tumor (COAD-colon adenocarcinoma; LUAD-lung adenocarcinoma; PAAD-pancreatic adenocarcinoma) or GTEX normal control datasets are plotted. b NSCLC expression data (GSE31852) were split into two groups by KRAS-mutation status (KRAS-mutated n = 24, KRAS WT n = 100) and analyzed for log² FSP1 expression. c, d PDAC expression data from Janky et al. [38] tumor n = 118, normal n = 13 were analyzed for log2 FSP1 expression in tumor as compared to adjacent normal as well as co-expression of FSP1 with NRF2 within tumor tissue. e, f PDAC expression data from Pei et al. [37] tumor n = 36, normal n = 15 were analyzed as in c, d. g Genes significantly co-expressed with FSP1 (r ≥ 0.3, FDR < 0.01) within the PDAC TCGA dataset were analyzed for transcription factor binding motifs by gene-set enrichment (GSEA) and -log10-transformed false discovery rates (FDR) of significantly enriched motifs are plotted. h Kaplan Meier survival of relapse-free survival in PDAC patients n = 69 according to FSP1 expression high versus low split by median is shown. Data were analyzed by and downloaded from KM plotter [58]. Whiskers are shown from min to max. Two-tailed t test (a, b, c, e) and log-rank test (h), ****p < 0.0001, **p < 0.01.